Acumen Pharmaceuticals, INC Form 4 insider transactions

Director Derrell Porter exercised stock options and sold shares of Acumen Pharmaceuticals, Inc. (ABOS) between June 15 and June 17, 2026.

Nathan B. Fountain, a Director at Acumen Pharmaceuticals, Inc., reported a sale of 6,400 shares of common stock on June 9, 2026.

Acumen Pharmaceuticals director Laura Stoppel received a grant of restricted stock units and stock options as part of her board compensation.

Director Nathan B. Fountain received a grant of 35,500 restricted stock units and 53,250 stock options.

Director Kimberlee C. Drapkin was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Director John A. Stalfort III was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Director Derrell Porter was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Director Jeffrey L. Ives was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Director George Golumbeski was granted 35,500 restricted stock units and options to purchase 53,250 shares of Acumen Pharmaceuticals.

Director Laura Stoppel was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals' Chief Legal Officer, Derek M. Meisner, exercised stock options and subsequently sold 9,406 shares of common stock under a pre-arranged 10b5-1 trading plan.

Acumen Pharmaceuticals' Chief Legal Officer, Derek Meisner, exercised stock options and subsequently sold 17,756 shares of common stock through a pre-arranged 10b5-1 trading plan.

Acumen Pharmaceuticals' Chief Legal Officer, Derek M. Meisner, sold a total of 8,934 shares of common stock across three transactions in late January 2026.

Acumen Pharmaceuticals' Chief Medical Officer, Eric Siemers, sold common stock to cover tax withholding obligations related to restricted stock unit vesting.

Acumen Pharmaceuticals' CFO and Chief Business Officer, Matt Zuga, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Acumen Pharmaceuticals CEO Daniel O'Connell sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Acumen Pharmaceuticals' COO, Russell Barton, sold common stock to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

Acumen Pharmaceuticals CEO Daniel O'Connell received 299,800 restricted stock units and 450,000 stock options, signaling long-term incentive alignment.

Acumen Pharmaceuticals' CFO & Chief Business Officer, Matt Zuga, was granted 99,133 restricted stock units and options to purchase 148,700 shares of common stock.

Acumen Pharmaceuticals, Inc. granted 99,133 restricted stock units and 148,700 stock options to Chief Legal Officer Derek M. Meisner as part of his compensation.

Acumen Pharmaceuticals' Chief Medical Officer, Eric Siemers, acquired 99,133 restricted stock units and 148,700 employee stock options on January 16, 2026.

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, received significant equity awards, including 84,600 restricted stock units and options for 126,900 shares, reinforcing long-term alignment with shareholder interests.

Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, received significant equity awards including restricted stock units and stock options.

Acumen Pharmaceuticals, Inc. granted 166,867 restricted stock units and options for 250,300 shares to President and CDO James J. Doherty.

Acumen Pharmaceuticals' CFO and Chief Business Officer, Matt Zuga, sold 6,888 shares of common stock at a weighted average price of $1.8166 to cover tax withholding obligations related to RSU vesting.

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, sold 3,530 shares of common stock to cover tax withholding obligations.

Acumen Pharmaceuticals' Chief Legal Officer, Derek M. Meisner, sold 50,659 shares of common stock in multiple transactions in January 2026, primarily under a pre-arranged 10b5-1 trading plan.

Acumen Pharmaceuticals CEO Daniel O'Connell sold shares to cover tax withholding obligations related to restricted stock unit vesting under a pre-arranged 10b5-1 plan.

Acumen Pharmaceuticals' President and CDO, James J. Doherty, sold common stock totaling 8,167 shares over two days to cover tax withholding obligations from RSU vesting.

Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, sold 1,097 shares of common stock to cover tax withholding obligations.